News

A sarcoidosis patient and ardent supporter of the Foundation for Sarcoidosis Research (FSR) was dubbed a “warrior” by the nonprofit for competing in the Ironman 70.3 Chattanooga triathlon, in Tennessee, to raise awareness of the rare condition as well as funds to fight it. The competition, held…

The lungs are affected in nearly everyone diagnosed with sarcoidosis in the Netherlands, but most patients in the country don’t have disease severe enough to warrant systemic immune-suppressing treatments at the time of diagnosis. That’s according to the findings of a new study, “Organ involvement in…

The Phase 2 clinical trial RESOLVE-Lung, which is testing namilumab as a treatment for people with chronic pulmonary sarcoidosis, is now fully enrolled. According to Kinevant Sciences, the therapy’s developer, 107 patients with hard-to-treat pulmonary sarcoidosis — disease that’s “not well-controlled despite currently available treatment” — have been…

Treatment with Remicade (infliximab) is generally effective for controlling sarcoidosis when it affects the nervous system or liver, but patients whose disease affects the skin or skeletal system aren’t as likely to respond to it, a study reports. “[Remicade] shows promise for treating patients with sarcoidosis, particularly with…

Walgreens and the Foundation for Sarcoidosis Research (FSR) have renewed their partnership to raise awareness about sarcoidosis and the importance of spring respiratory vaccines, as part of this April’s Sarcoidosis Awareness Month. Until the end of the month, all Alabama-based Walgreens stores will provide informational resources to…

More than half of sarcoidosis patients who were subjected to eye examinations were diagnosed with uveitis, an eye inflammation that may cause vision loss, according to a recent study. Despite most of those diagnosed patients showing acute symptoms, almost a quarter of those completely asymptomatic also had the…

A first patient has been dosed in Scotland as part of Molecure’s Phase 2 clinical trial — taking place in the U.S. and Europe — that will test the pulmonary sarcoidosis treatment candidate OATD-01 versus a placebo. “The first administration to a patient with pulmonary sarcoidosis is the realization…

Saying “sarcoidosis” can be problematic for some, so the Foundation for Sarcoidosis Research (FSR) will focus on the condition’s pronunciation as part of this year’s National Sarcoidosis Awareness Month, which is observed each April. Sarcoidosis is also difficult to diagnose, and therapies can only manage its symptoms.

A test that detects disease-specific antibodies in the blood could help to diagnose sarcoidosis more quickly and easily, according to a recent study. “More testing needs to be completed before this screening method is ready for clinical use, but it’s possible that could be a reality within a few…

Acthar Gel (repository corticotropin injection) treats African Americans with sarcoidosis as effectively as it does patients of other races, a study suggests. The study, “Acthar Gel in African Americans versus Non-African Americans with Symptomatic Sarcoidosis: Physician Assessment of Patient Medical Records,” was published in Therapeutics…